Early studies showed a small, statistically detectable weight-loss signal at some doses, but larger and longer trials did not separate clearly from placebo on their primary endpoints, and the drug was not pursued to approval for obesity
Comparison Both work on fat metabolism
it is not a claim of effect, benefit or suitability for any person
This can cause a gradual loss of vision and result in blind spots
Each note below is a research-framed summary using compliance-safe wording
The therapeutic stability window for most lyophilised peptides, including 5-Amino-1MQ, is 1025mg/mL this range balances solubility, aggregation prevention, and minimal oxidative exposure throughout the 28-day refrigerated lifespan